Pfizer Provides Topline Results From Phase 3 Study Of Torisel(R) As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) - Marketwatch

About SUTENT((R)) (sunitinib malate) SUTENT is an oral multi-kinase inhibitor approved for the treatment of advanced renal cell carcinoma (RCC), gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib ...

Disappointing Data on Pfizer Drug - Analyst Blog - Boston Globe

The company is looking to expand Torisel’s label for use in advanced renal cell carcinoma (RCC) patients whose disease has progressed while on or after being treated with Sutent. As far as the secondary endpoint -- overall survival -- was ...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel® As Second-Line Treatment In Advanced Renal Cell Carcinoma (RCC) - Yahoo Finance

Pfizer Inc announced today that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL ® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT ® (sunitinib malate) therapy ...

Disappointing Data on Pfizer Drug - Zacks.com

The company is looking to expand Torisel’s label for use in advanced renal cell carcinoma (RCC) patients whose disease has progressed while on or after being treated with Sutent. Results from the phase III INTORSECT (B1771003) study showed that Torisel ...

Pfizer’s Torisel Misses Endpoints in Renal Cell Carcinoma Trial Testing Second-Line Setting - Genetic Engineering News

The trial compared Torisel and Nexavar in patients whose disease had progressed on or after treatment with the company’s approved drug Sutent. Although PFS was numerically higher in patients treated with Torisel, the difference was not ...

Drug Fails: At Least It's Approved Already - Daily Finance

Wyeth, which Pfizer bought, went after the in-need group first. Pfizer's Sutent is also approved as first-line treatment without the need for the poor prognosis, but some 40% to 65% of kidney cancer patients require another treatment.

Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting - Yahoo Finance

SUTENT is indicated for the treatment of advanced renal cell carcinoma (RCC). SUTENT is an oral multi-kinase inhibitor that works by blocking multiple molecular targets implicated in the growth, proliferation and spread of cancer. Two important ...

Pfizer Provides Topline Results From Phase 3 Study Of Torisel As Second-Line Treatment - The FINANCIAL

The FINANCIAL -- Pfizer Inc announced that the Phase 3 INTORSECT study, evaluating TORISEL in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT therapy, did not meet the primary endpoint of prolonging ...

BUYINS.NET: Market Maker Surveillance Report. PFE, NOK, INTC… - TMCnet

It also offers Zyvox for gram-positive pathogens; Premarin for menopausal symptoms; Sutent for renal cell carcinoma; Geodon/Zeldox for schizophrenia; Detrol/Detrol LA for overactive bladder; Zosyn/Tazocin, an intravenous antibiotic; Genotropin ...

Hot Stock Research for Pfizer, PepsiCo, Duke Energy, Regions Financial, Peabody Energy, and Renren - Sacramento Bee

in patients with advanced renal cell carcinoma or RCC whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not achieve the primary endpoint of prolonging progression free survival or PFS when compared to sorafenib.